Journal of Clinical Pathways

From the Field: Cost and Clinical Implications of Utilizing Homologous Recombination Deficiency Status to Guide First-Line Maintenance Therapy Selection in Advanced Ovarian Cancer In the latest issue of Journal of Clinical Pathways (Volume 10, Issue 6), Daniel Simmons, PharmD MS RPh, et al, details a study model on the clinical outcomes and costs associated with utilizing an HRD biomarker-guided (BMG) approach to first-line AOC maintenance compared with a non-biomarker-guided (NBMG) approach. Study data suggests using a BMG approach based on HRD test results to pre­scribe first-line AOC maintenance therapy may reduce overall cost of care and improve clinical and economic outcomes. Read the full article to learn more: https://lnkd.in/eaDW3QZW #JournalofClinicalPathways #OncologyCare #ClinicalPathways #HRD #OvarianCancer

Enhanced AI Model Outperforms Traditional Techniques in Endometrial Cancer Diagnosis A groundbreaking AI model has shown remarkable improvements in diagnosing high-risk endometrial cancer (EC) and predicting postoperative recurrence, outperforming traditional methods. Published in Scientific Reports, this enhanced version of the ResNet-101 deep learning model incorporates spatial and channel attention mechanisms, achieving an area under the curve (AUC) of 0.918 for high-risk diagnosis and 0.926 for predicting recurrence. The study, which analyzed MRI data from 210 EC patients, highlights the model's ability to identify key areas in MRI scans, leading to earlier detection and more personalized treatment strategies. The results showed significant improvements in accuracy, precision, recall, and F1 scores compared to traditional models. Read the full article to learn more: https://lnkd.in/egYwkJaU #JournalofClinicalPathways #AIinHealthcare #EndometrialCancer #CancerDiagnosis #MachineLearning #MedicalInnovation #PrecisionMedicine #Oncology #HealthTech

Addressing Racial and Ethnic Disparities in Cancer Clinical Trial Access Despite progress in cancer research, racial and ethnic disparities in clinical trial participation persist, limiting access to investigational therapies for diverse populations. A recent study in JNCI Cancer Spectrum explored how social determinants of health (SDOH) contribute to these inequities, using a nationwide electronic health record (EHR) database. To address these challenges, researchers call for targeted interventions, such as transportation support, multilingual recruitment, and expanding trial access to community-based centers. Legislative efforts like the Food and Drug Omnibus Reform Act of 2022 also highlight the need for diversity in clinical trials, requiring drug sponsors to submit diversity plans to the FDA starting in 2024. This study underscores the urgent need for policy changes and practical solutions to ensure cancer trials are more inclusive and produce results that benefit all patients. Read the full article to learn more: https://lnkd.in/ekb-Z_SH #JournalofClinicalPathways #CancerResearch #ClinicalTrials #HealthEquity #SocialDeterminantsOfHealth #DiversityInResearch #Oncology #PublicHealth

New Case Study: Development and Analysis of a Treatment Timeliness Dashboard for Patients With Head and Neck Cancer at a Tertiary Academic Multidisciplinary Clinic Improving timeliness represents a critical opportunity to maximize patient experience, quality of care, and overall health of a co-located multidis­ciplinary cancer (MDC) program. In a Case Study published in the November/December Issue (Volume 10, Issue 6) of the Journal of Clinical Pathways, Ryan et al review a treatment timeline dashboard for treating patients with head and neck cancer using a primary nursing care coordination model as part of the pathway. Read the full article to learn more: https://lnkd.in/eyHcWMCV #JournalofClinicalPathways #JCP #HeadandNeckCancer #OncologyCare #OncologyClinicalPathways

Inside the Evolution of Oncology Pathways Research Cindy Chen, MBA, Head of Data Analytics at HMP Market Access Insights, dives into the challenges, adoption hurdles, and future trends shaping oncology pathways research in an exclusive interview with the Journal of Clinical Pathways. Drawing from her thought-provoking session with Lee Blansett at the Clinical Pathways Congress + Cancer Care Business Exchange, Cindy shares actionable insights that bridge research and real-world application. Discover how oncology pathways are evolving to meet the needs of providers, patients, and manufacturers in an ever-changing healthcare landscape. Watch the full interview: https://lnkd.in/gFZrymRq #OncologyPathways #MarketAccessInsights #CancerCare #HealthcareResearch #OncologyLeadership #HMPMarketAccessInsights #Clinicalpathwayscongress #cancercarebusinessexchange

Factors Impacting the Development and Selection of Targeted Therapies for Patients With CLL In this interview, Matthew Davids, MD, discusses the latest targeted therapies for treating chronic lymphocytic leukemia (CLL), the challenges in developing these treatments, and how they are being used in the community oncology setting. "There are a number of challenges still in terms of developing targeted therapies for patients with CLL. One is that we have a lot of existing targeted therapies now, between BTK inhibitors, a very good BCL2 inhibitor, and other mechanisms. For many patients with CLL, they can do well just with these agents," said Dr Davids. Watch the interview to learn more: https://lnkd.in/e5GFP_8d #JournalofClinicalPathways #JCP #CLL #OncologyCare #TargetedTherapies

In this interview, Gordon Kuntz, moderator at the 2024 Clinical Pathways Congress and a pharma consultant, discusses the Delphi Method, a Predictable Cost of Care Model developed by the Predictable Cost of Care Working Group, which enhances oncology market access strategies by standardizing and broadening the economic modeling of cancer treatment costs beyond just drug prices, while aiming to inform pathway developers, payers, and practices. The group, which includes oncology pathway developers and pharma sponsors, seeks to address the complexity of cancer care costs—many of which are unrelated to the drug itself, such as side effect management and premeds. By establishing standardized, independently verifiable models, the goal is to help pharma, payers, and practices better understand and manage these costs, ultimately benefiting patients, healthcare providers, and the oncology ecosystem. This shift from focusing solely on drug costs to a broader view of total cancer care is essential as drugs become more expensive and the need for value-based healthcare increases. Watch the interview to learn more: https://lnkd.in/ee3unfKz #JournalofClinicalPathways #CPC #ClinicalPathwaysCongress #OncologyCare #MarketAccess #CostOfCare #ClinicalPathways #CancerTreatment

Featured Interview from Clinical Pathways Congress + Cancer Care Business Exchange 2024 In this interview, Carole Tremonti, RN, MBA, discusses how to build consensus for predictable cancer care costs from her experience working on the Delphi Method within the Predictable Cost of Care Working Group (PCOC). Learn about the following: 1. How clinical pathways drive transparency and collaboration in decision-making. 2. The innovative use of the Delphi Method by the PCOC to foster stakeholder consensus. 3. A groundbreaking pilot focusing on metastatic non-small cell lung cancer to create a cost-predictive model that balances equity and predictability. Access the full interview to learn how these efforts are shaping the future of cancer care. 👉 https://lnkd.in/dp65GpF6 #JournalofClinicalPathways #JCP #Oncology #CPCCBEX #CancerCare #ClinicalPathwaysCongress #CancerCareBusinessExchange #HealthEquity #CPC2024 #HealthcareInnovation

📢 Now Available: The Latest Issue of the Journal of Clinical Pathways! We're closing out 2024 with Volume 10, Issue 6, delivering cutting-edge insights to advance value-based oncology through innovation and equity. 📰 Highlights from this issue: 1. Clinical Pathways Research: Exploring challenges, adoption, and future trends, featuring Cindy Chen, MBA, Head of Research at HMP Market Access Insights 2. Policy Analysis: The intersection of public law and private sector employer plans, written by Randy Vogenberg, PhD 3. Multidisciplinary Care: Evolving oncology clinical pathways in chronic lymphocytic leukemia (CLL), featuring Shaffee Bacchus, Pharm.D, FASN, at AbbVie 4. AI and Equity: Addressing bias in quality measurement, written by Maggie Dietrick, MPH; Palak Patel, MHA, and Tom Valuck from Real Chemistry 5. Case Study: Development and analysis of a treatment timeliness dashboard for head and neck cancer patients at a tertiary academic multidisciplinary clinic. 6. Cost & Clinical Insights: Implications of using homologous recombination deficiency status to guide first-line maintenance therapy selection in advanced ovarian cancer, written by Daniel Simmons, PharmD MS RPh et al. As we celebrate another impactful year, we thank our contributors, readers, and the community for driving meaningful conversations in oncology care. https://bit.ly/41elMXa 💬 Which article resonates with you most? Share your thoughts below! #JournalofClinicalPathways #JCP #ValueBasedCare #Oncology #ClinicalPathways #HealthcareInnovation #EquityInHealthcare

In an interview with the Journal of Clinical Pathways, Joe Y. Chang, MD, PhD, explores advancements in NSCLC treatment pathways, emphasizing the integration of immunotherapy and precision radiotherapy, the role of value-based care in palliative approaches, and the potential of artificial intelligence to optimize individualized treatment strategies. Check out the full interview here: https://lnkd.in/dggiUhhm #JournalOfClinicalPathways #JCP #NSCLC #immunotherapy #precisionradiotherapy